Tetraphase Pharmaceuticals to Present at Wedbush Life Sciences Conference

2014 Wedbush Life Sciences Conference

WATERTOWN, Mass.--()--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant bacteria, today announced that Guy Macdonald, Tetraphase President and Chief Executive Officer, will present at the annual Wedbush Life Sciences Conference on Wednesday, August 13 at 2:30 p.m. Eastern Time. The conference will take place at Le Parker Meridien in New York.

About Tetraphase Pharmaceuticals, Inc.

Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC). Tetraphase's lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic in the IGNITE program (Investigating Gram-negative Infections Treated with Eravacycline). Under this program, two Phase 3 clinical trials are ongoing: IGNITE 1 for the indication of complicated intra-abdominal infections (cIAI) and IGNITE 2 for complicated urinary tract infections (cUTI). Tetraphase has created more than 3,000 novel tetracycline analogs using its technology platform; in addition to eravacycline, Tetraphase has generated multiple preclinical antibiotic candidates that are currently being evaluated for clinical suitability. Please visit www.tphase.com for more company information.


Tetraphase Pharmaceuticals
David Lubner, 617-715-3551
Argot Partners
Susan Kim, 212-600-1902
Sam Brown Inc.
Mike Beyer, 773-463-4211

Tetraphase Pharmaceuticals, Inc.